UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    May

    23

    UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

    Read More

    May

    10

    Moms Really Can Do It All - Meet Tracy: a Mom, Caregiver, Neuroscientist, and Advocate in the Rare Disease Community

    Read More

    Apr

    12

    UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting

    Read More

    Mar

    19

    Patty Fritz and Bianca Anderson Recognized by the Healthcare Businesswomen’s Association (HBA) as UCB Luminary and Rising Star

    Read More

    Mar

    09

    First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

    Read More

    Mar

    08

    BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

    Read More

    Mar

    07

    Innovating and collaborating in immuno-dermatology: a dialogue with UCB’s Simon Lucas & Camille Lee

    Read More

    Mar

    06

    Putting People First to Create a More Sustainable Healthcare System

    Read More

    Feb

    28

    UCB on Growth Path for a Decade Plus

    Read More

    Feb

    22

    Rare Disease Day 2024: The Moment is Now to Be Patient-First to Deliver for People Living with Rare Diseases

    Read More